US 12,282,019 B2
Compositions and methods to detect gastrointestinal disease
Sunyoung Kim, New Orleans, LA (US); Zeromeh Gerber, Las Vegas, NV (US); Duna Penn, New Orleans, LA (US); Carl Sabottke, New Orleans, LA (US); and Rebecca Buckley, Metairie, LA (US)
Assigned to THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE, Baton Rouge, LA (US)
Filed by The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA (US)
Filed on Sep. 30, 2022, as Appl. No. 17/957,853.
Application 17/957,853 is a continuation of application No. 16/267,120, filed on Feb. 4, 2019, granted, now 11,493,515.
Application 16/267,120 is a continuation in part of application No. PCT/US2017/045588, filed on Aug. 4, 2017.
Claims priority of provisional application 62/524,306, filed on Jun. 23, 2017.
Claims priority of provisional application 62/467,487, filed on Mar. 6, 2017.
Claims priority of provisional application 62/378,820, filed on Aug. 24, 2016.
Claims priority of provisional application 62/371,131, filed on Aug. 4, 2016.
Prior Publication US 2023/0184769 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); A23K 10/00 (2016.01); A23K 20/195 (2016.01); A23L 33/00 (2016.01); A23L 33/17 (2016.01); A61K 35/741 (2015.01); A61P 1/00 (2006.01); A61P 29/00 (2006.01); C07K 16/40 (2006.01); C12Q 1/42 (2006.01); C12Q 1/68 (2018.01); G01N 33/573 (2006.01); A61K 9/00 (2006.01)
CPC G01N 33/573 (2013.01) [A23K 10/00 (2016.05); A23K 20/195 (2016.05); A23L 33/17 (2016.08); A23L 33/40 (2016.08); A61K 35/741 (2013.01); A61P 1/00 (2018.01); A61P 29/00 (2018.01); C07K 16/40 (2013.01); C12Q 1/42 (2013.01); C12Q 1/68 (2013.01); A23V 2002/00 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); G01N 2333/916 (2013.01); G01N 2800/065 (2013.01)] 19 Claims
 
1. A method of identifying an infant afflicted with early-stage necrotizing enterocolitis, the method comprising:
detecting the presence of at least one early-stage necrotizing enterocolitis biomarker in a stool sample from the infant,
wherein the early-stage necrotizing enterocolitis biomarker comprises increased iAP protein level compared with age-matched controls, increased total protein level compared with age-matched controls, or a combination thereof,
wherein the early-stage necrotizing enterocolitis biomarker is indicative of infant afflicted with early-stage necrotizing enterocolitis; and
treating the infant afflicted with early-stage necrotizing enterocolitis, wherein treating comprises administering an effective amount of an antibiotic, a probiotic, an intravenous fluid, an iAP replacement composition, a small molecule effector of catalytic activity, an anti-inflammatory agent, parenteral or intravenous nutrition, a biologic, or a prebiotic; withholding oral feeding; surgery; or a combination thereof.